This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Welcome to
InOncology.com

A knowledge hub developed to provide information and education in oncology for healthcare professionals.

Rate this

WCLC 2019

Access materials presented at the annual WCLC congress

7–10 September 2019
8 Publications
8 Downloads
Discover more about our activities at WCLC 2019

Our activities at ESMO 2019

27 September–1 October 2019
Barcelona, Spain
Booth #401
1 Symposium
6 publications
GioTag study animation

Watch this animation about sequential therapy with afatinib* followed by osimertinib

CRC in focus: information and hot topics

Explore our educational resources on lung and GI cancers

Investigational compounds

Learn more about our oncology clinical trial programme

InOncology Slide Bank

Explore our educational module on NSCLC

InOncology Slide Bank

Browse the real-world evidence module

Uncommon EGFR mutations

Discover more about data on use of afatinib in patients with NSCLC and uncommon EGFR mutations

InOncology article library

Search this library for published papers about afatinib and nintedanib¶

Nintedanib** after ICI therapy

Learn more about emerging data from the VARGADO study
Physicians’ insights
Nicolas Girard
Prof Nicolas Girard

Prolonging the chemotherapy-free period in EGFRM+ NSCLC

FIND OUT MORE
Professor Martin Schuler
Prof Martin Schuler

Improving outcomes for patients with brain metastases

FIND OUT MORE
Prof Reck discusses recent changes and sequencing strategies in non mutated, non-squamous advanced NSCLC
Prof Martin Reck

Recent changes and sequencing strategies in non-mutated, non-squamous advanced NSCLC

FIND OUT MORE
Barbara Melosky
Dr Barbara Melosky

Clinical considerations in EGFRm+ NSCLC: does treatment sequence matter?

FIND OUT MORE
Vanesa Gregorc
Prof Vanesa Gregorc

Sequencing algorithms in NSCLC

FIND OUT MORE
Professor Nir Pelend discusses treatment strategies in EGFRm+ NSCLC
Prof Nir Peled

Treatment strategies in EGFRm+ NSCLC

FIND OUT MORE
<
>

*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.